Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens

Br J Haematol. 2006 Nov;135(3):367-73. doi: 10.1111/j.1365-2141.2006.06302.x. Epub 2006 Sep 14.

Abstract

Allogeneic haematopoietic stem cell transplantation remains the only curative treatment of myelofibrosis with myeloid metaplasia (MMM). Previous reports have indicated significant treatment-related mortality (TRM) for patients transplanted after myeloablative conditioning but superior survival has been reported after reduced-intensity conditioning (RIC). We report the results of a survey of all allogeneic transplantations for MMM performed in Sweden at six transplant units between 1982 and 2004. Twenty-seven patients were transplanted; 17 with a myeloablative conditioning regimen and 10 with RIC. The median age was 50 years (5-63 years) at transplantation. After a median follow up of 55 months, 20 patients are alive. TRM was 10% in the RIC group and 30% in the myeloablative group. There was no difference in survival for high or low-risk patients according to Cervantes score or between sibling and unrelated donor transplantations.

MeSH terms

  • Adult
  • Antilymphocyte Serum / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Busulfan / therapeutic use
  • Child, Preschool
  • Cyclophosphamide / therapeutic use
  • Female
  • Graft vs Host Disease / immunology
  • Hematopoietic Stem Cell Transplantation / methods*
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Lymphocyte Transfusion
  • Male
  • Middle Aged
  • Postoperative Complications
  • Primary Myelofibrosis / mortality
  • Primary Myelofibrosis / radiotherapy
  • Primary Myelofibrosis / surgery*
  • Spleen / pathology
  • Time Factors
  • Treatment Outcome
  • Vidarabine / analogs & derivatives
  • Vidarabine / therapeutic use
  • Whole-Body Irradiation / methods

Substances

  • Antilymphocyte Serum
  • Antineoplastic Agents
  • Immunosuppressive Agents
  • Cyclophosphamide
  • Vidarabine
  • Busulfan
  • fludarabine